Arch Therapeutics Net income (Q2, 2020)-731.9 K
Arch Therapeutics EBIT (Q2, 2020)-1.2 M
Arch Therapeutics Cash, 31-Mar-20201.8 M

Arch Therapeutics Funding

Summary Metrics

Founding Date

2006

Arch Therapeutics total Funding

$5.9 m

Arch Therapeutics latest funding size

$3 m

Time since last funding

5 years ago
Arch Therapeutics's latest funding round in July 2015 was reported to be $3 m. In total, Arch Therapeutics has raised $5.9 m

Arch Therapeutics Income Statement

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cost of goods sold

Gross profit

R&D expense

218.9k1.5m1.8m1.7m2.1m2.9m2.4m

General and administrative expense

36.6k1.5m3.1m3.7m4.4m5.2m4.6m4.0m

Operating expense total

36.6k1.7m4.6m5.5m6.1m7.3m7.4m6.4m

EBIT

(1.7m)(4.6m)(5.5m)(6.1m)(7.3m)(7.4m)(6.4m)

Interest expense

Pre tax profit

(36.6k)

Income tax expense

Net Income

(36.6k)(1.9m)(8.1m)(2.9m)(6.0m)(7.8m)(4.8m)(4.5m)

Arch Therapeutics Balance Sheet

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

4.5k557.3k833.5k4.0m5.0m6.0m4.7m2.2m

Accounts Receivable

50.0m

Prepaid Expenses

250.019.6k43.5k42.9k85.3k151.8k362.7k

Inventories

107.8k346.6k

Current Assets

4.7k1.6m877.0k4.0m5.1m6.1m4.8m2.9m

PP&E

322.07.2k17.3k9.0k

Total Assets

1.6m877.0k4.0m5.1m6.1m4.8m2.9m

Accounts Payable

25.0314.8k175.8k231.8k374.9k264.9k160.9k533.6k

Current Liabilities

6.1k455.6k2.7m1.3m1.9m433.5k288.4k713.8k

Long-term debt

944.7k955.8k966.8k

Non-Current Liabilities

944.7k5.0m1.2m104.5k3.4m3.2m3.0m

Total Debt

944.7k955.8k966.8k

Total Liabilities

1.4m7.8m2.5m2.0m3.9m3.5m3.7m

Common Stock

6.0k60.1k72.1k107.4k149.9k159.8k172.6k

Additional Paid-in Capital

34.3k4.8m5.8m17.2m24.7m31.6m35.5m37.9m

Retained Earnings

(12.8m)(15.7m)(21.7m)(29.5m)(34.3m)(38.9m)

Total Equity

(1.3k)187.0k(6.9m)1.5m3.2m2.2m1.4m(807.3k)

Debt to Equity Ratio

5.1 x

Debt to Assets Ratio

0.6 x

Financial Leverage

8.5 x-0.1 x2.6 x1.6 x2.7 x3.6 x-3.6 x

Quarterly

USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

5.0k19.9k3.2k52.0476.4k945.4k2.6m1.8m782.7k573.6k3.3m2.8m1.7m5.7m3.8m7.2m6.2m5.0m3.4m6.5m3.4m2.0m3.2m3.0m1.8m

Prepaid Expenses

370.0250.0250.01.1k39.6k30.9k32.2k41.8k32.4k44.1k53.0k90.1k158.0k110.1k345.2k151.3k71.4k69.9k87.7k240.0k453.1k594.5k329.5k140.7k

Inventories

200.4k954.0k

Current Assets

5.0k20.3k3.5k302.0477.5k985.0k2.7m1.8m824.4k606.0k3.3m2.9m1.8m5.9m3.9m7.6m6.3m5.0m3.4m6.6m3.6m2.4m3.8m3.6m2.9m

PP&E

61.0322.0322.04.2k3.8k3.5k9.9k15.2k19.1k15.5k13.7k10.9k9.5k7.8k

Total Assets

477.6k995.4k2.7m1.8m824.4k606.0k3.3m2.9m1.8m5.9m3.9m7.6m6.3m5.0m3.5m6.6m3.6m2.4m3.8m3.6m2.9m

Accounts Payable

875.025.01.5k307.5k309.6k104.2k166.0k294.2k204.1k499.7k267.9k135.6k492.9k272.3k208.6k206.1k289.3k317.5k183.2k130.6k175.6k128.7k401.5k724.3k

Short-term debt

100.0k754.8k

Current Liabilities

61.0936.06.1k7.5k419.3k512.8k4.4m3.5m995.0k1.4m1.9m748.7k399.0k682.2k1.4m362.8k370.3k470.5k392.0k358.8k276.6k280.6k270.5k631.3k817.2k

Long-term debt

947.5k950.2k953.0k958.5k961.3k964.1k969.6k972.4k975.1k

Non-Current Liabilities

972.5k6.8m6.3m5.3m5.1m7.5m1.2m1.2m1.3m2.6m2.6m1.5m1.0m4.0m4.0m2.3m3.7m3.0m2.6m

Total Debt

947.5k950.2k953.0k958.5k961.3k964.1k969.6k1.1m975.1k754.8k

Total Liabilities

419.3k1.5m11.2m9.7m6.3m6.5m9.4m2.0m1.6m2.0m1.4m3.0m2.9m1.9m1.4m4.3m4.3m2.6m4.0m3.7m3.4m

Common Stock

4.0k6.0k6.0k6.0k58.6k60.1k71.9k72.0k76.1k76.1k92.7k109.2k110.4k131.0k136.1k147.0k147.0k150.3k150.3k150.5k162.2k163.9k172.6k186.9k186.9k

Additional Paid-in Capital

16.0k34.3k34.3k34.3k3.7m4.9m5.3m5.4m6.9m7.2m8.6m17.7m18.1m23.7m25.5m29.4m30.0m32.1m32.6m32.8m36.1m36.4m37.7m40.2m40.5m

Retained Earnings

(12.4m)(13.2m)(14.6m)(16.9m)(18.1m)(19.9m)(23.1m)(25.0m)(26.8m)(29.1m)(30.7m)(32.9m)(36.9m)(36.7m)(38.0m)(40.5m)(41.3m)

Total Equity

5.0k19.4k(2.6k)(7.2k)58.3k(489.9k)(8.5m)(7.9m)(5.4m)(5.9m)(6.1m)909.9k117.5k3.9m2.5m4.6m3.4m3.1m2.1m2.3m(664.1k)(200.9k)(171.5k)(100.8k)(535.5k)

Debt to Equity Ratio

-1.9 x-0.1 x-0.1 x

Debt to Assets Ratio

1 x0.4 x0.5 x

Financial Leverage

8.2 x-2 x-0.3 x-0.2 x-0.2 x-0.1 x-0.5 x3.2 x15 x1.5 x1.6 x1.7 x1.9 x1.6 x1.7 x2.9 x-5.5 x-12.1 x-22.1 x-35.4 x-5.4 x

Arch Therapeutics Cash Flow

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(36.6k)(1.9m)(8.1m)(2.9m)(6.0m)(7.8m)(4.8m)(4.5m)

Depreciation and Amortization

586.0322.01.5k5.3k8.2k

Inventories

(346.6k)

Accounts Payable

25.056.3k(138.9k)55.9k137.4k(110.0k)(103.9k)372.6k

Cash From Operating Activities

(33.8k)(1.3m)(3.3m)(4.2m)(4.7m)(5.6m)(5.9m)(5.3m)

Purchases of PP&E

(8.7k)(15.4k)

Cash From Investing Activities

(8.7k)(15.4k)

Short-term Borrowings

(1.0m)

Cash From Financing Activities

20.3k1.9m3.6m7.4m5.8m6.6m4.6m2.8m

Net Change in Cash

(13.5k)540.2k276.2k3.1m1.1m957.6k(1.3m)(2.5m)

Interest Paid

98.3k361.3k

Income Taxes Paid

Arch Therapeutics Ratios

USDY, 2020

Financial Leverage

-5.4 x